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Abstract Purpose: Although existence of humoral immunity has been previously shown in malignant
pleural effusions, only a limited number of immunogenic tumor-associated antigens (TAA) have
been identified and associated with lung cancer. In this study, we intended to identify moreTAAs
in pleural effusion ^ derived tumor cells.
Experimental Design:Usingmorphologically normal lung tissues as a control lysate inWestern
blotting analyses, 54 tumor samples were screened with autologous effusion antibodies.
Biochemical purification and mass spectrometric identification of TAAs were done using estab-
lished effusion tumor cell lines as antigen sources.We identified a p48 antigen as a-enolase
(ENO1). Semiquantitative immunohistochemistry was used to evaluate expression status of
ENO1in the tissue samples of 80 patients with non ^ small cell lung cancer (NSCLC) and then
correlated with clinical variables.
Results:Using ENO1-specifc antiserum, up-regulationof ENO1expression in effusion tumor cells
from11of 17 patients was clearly observed compared with human normal lung primary epithelial
and non-cancer-associated effusion cells. Immunohistochemical studies consistently showed
high level of ENO1expression in all the tumors we have examined thus far. Log-rank and Cox’s
analyses of ENO1expression status revealed that its expression level in primary tumors was a
key factor contributing to overall- and progression-free survivals of patients (P < 0.05).The same
result was also obtained in the early stage of NSCLC patients, showing that tumors expressing
relatively higher ENO1level were tightly correlated with poorer survival outcomes.
Conclusions: Our data strongly support a prognostic role of ENO1in determining tumor malig-
nancy of patients with NSCLC.
Identification of immunogenic tumor-associated molecules is
not only a crucial step in understanding their roles on a
molecular basis in cancer immunology, but also of interest for
use in clinical diagnostic or therapeutic applications. Malignant
pleural effusion is usually enriched with infiltrating lympho-
cytes and tumor cells. Therefore, it can be considered a local
microenvironment for tumor cells. Tumor-associated immune
complexes (1, 2) or autoantibodies (3, 4) have been found in
effusion fluids, whereas only a limited number of immunore-
active targets were identified and associated with lung cancer
(5, 6). Therefore, we collected malignant effusions from lung
cancer patients to identify additional potential tumor-associated
antigens using purified autologous effusion antibodies as
probes. In the present study, we identified a p48 antigen as
human a-enolase (ENO1) through biochemical enrichment
procedures and mass spectrometric analyses.
Enolase was originally characterized as an enzyme involved
in glycolytic metabolism. More recent evidence, however,
shows that enolase is a multifunctional protein. In mammalian
cells, three isoforms of enolase have been found. They are
designated as a-(ENO1), h-(ENO3), and g-(ENO2) enolases.
The expression of these isoforms is developmentally regulated
Imaging, Diagnosis, Prognosis
Authors’ Affiliations: 1Division of Chest Medicine, Department of Internal
Medicine and 2Division of Thoracic Surgery, Department of Surgery, Taichung
Veterans General Hospital; 3School of Medicine, China Medical University ;
4Institute of Biomedical Sciences, National Chung-Hsing University; 5China
Medical University Hospital, Taichung, Taiwan, Republic of China and 6National
Institute of Cancer Research and 7Immunology Group, National Health Research
Institutes; 8Graduate Institute of Cell and Molecular Biology, Taipei Medical
University; 9Department of Laboratory Medicine, National Taiwan University
Hospital; 10Division of Pulmonary and Critical Care Medicine, SunYat-Sen Cancer
Center; Departments of 11General Surgery and 12Pathology,Taipei Veterans General
Hospital; 13Department of Pathology, CardinalTien Hospital,Taipei,Taiwan, Republic
of China
Received 2/13/06; revised 7/8/06; accepted 7/21/06.
Grant support: National Health Research Institutes Intramural Research Program
and National Science Council, Republic of China grant NSC91-3112-P400-008.
The costs of publication of this article were defrayed in part by the payment of page
charges.This article must therefore be hereby marked advertisement in accordance
with18 U.S.C. Section1734 solely to indicate this fact.
Note: Supplementary data for this article are available at Clinical Cancer Research
Online (http://clincancerres.aacrjournals.org/).
G-C. Chang and N-Y. Shih contributed equally to this work.
Requests for reprints: Neng-Yao Shih, National Institute of Cancer Research,
National Health Research Institutes, 7th Floor, No. 161, Section 6, Min-Chuan East
Road,Taipei 114,Taiwan, Republic of China. Phone: 886-2-26534401, ext. 25136;
Fax: 886-2-27929654; E-mail: jshih@nhri.org.tw.
F2006 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-06-0324
www.aacrjournals.orgClin Cancer Res 2006;12(19) October1, 2006 5746
in a tissue-specific manner. ENO1 is widely distributed in a
variety of tissues, whereas ENO2 and ENO3 are exclusively
found in neuron/neuroendocrine and muscle tissues, respec-
tively (7). Enolases form heterodimers or homodimers to
convert 2-phosphoglycerate into phosphoenolpyruvate in
glycolysis. In addition to their glycolytic function, ENO1 was
recently found to exist on the cell surface functioning as one of
the plasminogen receptors (8), implying that it may play a role
in tissue invasion. In hypoxic situations, it also acts as a stress
protein that is up-regulated and speculated to provide protec-
tion to cells by increasing anaerobic metabolism (9). By using
an alternative translation start codon, ENO1 transcripts can be
translated into a MBP1-like p37, which is localized to nucleus
and binds to the c-myc P2 promoter (10).
Development of high titers of autoantibody against enolases
has been reported to be associated with a diverse range of
systemic or organ-specific autoimmune diseases (11). In
contrast, enolase-related autoantibody is rarely found in cancer
patients in spite of the fact that another isoform, g-enolase
(neuron-specific enolase; ENO2), is a product of several types
of tumors (12). One study identified ENO1 as antigenic target
on human oral cancer cells that was recognized by autologous
CD4+ T cells (13). Immunoreactive sera to ENO1 were also
recently found in 6.9% to 13.8% of patients with different
subtypes of lung cancer (14, 15), suggesting that it can be an
immunogenic target in cancer patients.
Changes in ENO1 gene regulation have been observed in
several cancer cell models, whereas the clinical correlation of
ENO1 expression to tumor states has not yet clearly been
defined. Up-regulation of ENO1 has been reported in several
highly tumorigenic or metastatic cell lines derived from either
alveolar type II pneumocytes (16), small cell lung cancer
(SCLC; ref. 17), or head and neck cancer (18). Similarly,
studies examining enzymatic activities in breast cancer con-
cluded a role for ENO1 in tumor progression (19). One recent
bioinformatics study using gene chips and expressed sequence
tag databases further supports a correlation between ENO1
expression and tumorigenicity as they found ubiquitously
overexpression of ENO1 in 18 of 24 types of cancer, including
lung cancer (20), strongly supporting its general pathophysio-
logic role in cancer formation. However, clinical correlation
between its expression status and tumor progression is quite
controversial (21, 22) due to use of antibodies with different
specificity for ENO1. Thus, we herein show specificity of our
antiserum to a-isoform by detection of known isoforms of
human enolase using Western blot and immunoprecipitation
analyses. Using this highly specific antiserum, we confirm that
ENO1 is significantly overexpressed in effusion-derived tumor
cells and tumor specimens of lung cancer. Coincidently, its
surface distribution is also detected and restricted in tumor
cells only. Immunohistochemical analyses show that expres-
sion status of ENO1 in tumor is inversely correlated with
prognoses of survival and disease recurrence for patients with
non-SCLC (NSCLC). Therefore, ENO1 can be not only a
potential target for targeting therapy, but also a potent
prognostic marker for NSCLC patients.
Materials andMethods
Malignant pleural effusions and sample processing. To identify
immunogenic tumor antigens in lung cancer, 54 malignant pleural
effusion samples were collected. Histologic subtypes of the samples,
depending on sample availability from our cooperated hospitals
between 2001 and 2002 (under permission from Institutional Review
Board, National Health Research Institutes, Taipei, Taiwan, Republic
of China), include 4 small cell carcinoma, 45 adenocarcinoma,
5 squamous carcinoma, as well as 21 patients with non-cancer-
associated diseases consisting of 13 pneumonia, 4 tuberculosis, and
4 heart disease. Separation of tumor cells from effusion-associated
lymphocytes was done using a serial gradient centrifugation with Ficoll-
Plaque Plus and Percoll (Pharmacia, Uppsala, Sweden) as described
previously (23). The purity of tumor cells in fraction as determined by
cytologic examinations was between 70% and 90%.
Effusion antibody preparation. The immunoglobulins of pleural
effusions were partially purified using ammonium sulfate precipitation.
One volume of effusion fluid was added dropwise with 0.66 volume of
saturated ammonium sulfate with constant mixing for 1 hour followed
by centrifugation at 10,000  g at 4jC for 10 minutes. The resultant
pellet was dissolved in 0.1 volume of distilled water and dialyzed
against PBS overnight.
Cells and flow cytometry analysis. The primary effusion tumor cells
were obtained from a 51-year-old patient (CA926) with poorly diffe-
rentiated lung adenocarcinoma and grown in DMEM supplemented
with 10% fetal bovine serum (Hyclone, Logan, UT), 1 mmol/L sodium
pyruvate (Invitrogen, Grand Island, NY), 0.1 mmol/L nonessential
amino acid (Sigma-Aldrich, St. Louis, MO), 2 mmol/L glutamine,
50 Ag/mL streptomycin, and 500 units/mL penicillin for two passages.
The NHRI-L89 (abbreviated as L89) cell line was originally obtained
from effusion tumor cells of a 36-year-old patient with stage IV lung
adenocarcinoma and characterized as cytokeratin (+)/calretinin ().
The cells have been cultured in RPMI 1640 supplemented with 5%
fetal bovine serum, 2 mmol/L glutamine, and antibiotics for at least
40 passages in vitro . Normal bronchial/tracheal and small airway
primary epithelial cells were purchased from Cambrex (Walkersville,
MD) and cultured in medium provided by the manufacturer.
For flow cytometry analysis, cells isolated from cancer-associated or
non-cancer-associated effusion fluids were cultured in ACL-4 (24) and
RPMI 1640 (1:1) for one or two passages. The intact whole cells were
stained with or without ENO1 antibody, visualized with goat
antiserum-conjugated Cy2 (Jackson ImmunoResearch Laboratories,
West Grove, PA), and analyzed using the FACScan flow cytometer
(Becton Dickinson, Franklin Lakes, NJ).
Protein purification and identification. The p48 antigen (ENO1) was
purified using DEAE anionic column, ammonium sulfate fractionation,
and long-range SDS-PAGE separation. The L89 cells were lysed with cell
lysis buffer [20 mmol/L Tris-HCl (pH 8.0), 150 mmol/L NaCl, 0.5%
NP40] containing protease inhibitor cocktail (Calbiochem, La Jolla,
CA). Approximately 45 mg of the detergent-soluble fraction were
fractionated in a HiTrap DEAE column (Amershan Biosciences,
Uppsala, Sweden) buffered with 20 mmol/L Tris-HCl (pH 7.0) and
eluted with increasing concentration of NaCl ranged from 0 to 1.0 mol/L
at 1 mL/min pressure. To determine the abundance of p48 antigen in
each fraction, the elutants were dialyzed against PBS and detected by
Western blot analysis using the CA926 effusion antibody as a probe.
Subsequently, the p48-enriched fraction (f2.5 mg) was subjected to
ammonium sulfate fractionation (25). Each dialyzed fraction (50 Ag)
was resolved on 10% SDS-PAGE in duplicate and visualized by quick
silver staining (26) or Western blotting. The putative p48 band on the
silver-stained gel was excised and analyzed by Babraham Bioscience
Technologies, Inc. (Cambridge, United Kingdom) using an application
programming interface Q-Star ESI-Quadrupole-TOF.
Gene cloning and antiserum generation. To generate recombinant
ENO1 protein, the gene was cloned out from L89 cells by reverse
transcription-PCR using gene-specific primers 5¶-GGTGGAATTCTATC-
TATTCTCAAGATCCATGCC-3¶ (forward) and 5¶-ACTCCATGGT-
TACTTGGCCAAGGGGTTTCT-3¶ (reverse). The resultant PCR fragment
was digested with EcoRI and NcoI, cloned into pGEX-KG vector, and
expressed in Escherichia coli cells to generate a recombinant protein
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fused with glutathione S-transferase (GST) tag. Protein purification was
done using glutathione-immobilized affinity chromatography as
recommended by a manufacturer (Sigma-Aldrich). ENO1 rabbit
antiserum raised by immunizing with the recombinant protein was
produced by Kelowna, Inc. (Taipei, Taiwan, Republic of China). To
avoid cross-reaction with the tag protein, the serum was further
absorbed with immobilized GST resins (Pierce, Rockford, IL).
To determine the isoform-specific recognition of CA926 antibodies
and the ENO1-specific rabbit antiserum, human ENO2 and ENO3 genes
were cloned out fromCA926 tumor cDNA and human heart (Stratagene,
La Jolla, CA), respectively, by reverse transcription-PCR. The isoform-
specific primers used for the gene cloning are listed as follows:
ENO2, 5¶-ATTGAATTCTTCCATAGAGAAGATCTGGGCCCGGGAGAT-3¶
(forward) and 5¶-ATTGAATTCTCACAGCACACTGGGATTACGGAAG-3¶
(reverse); ENO3 , 5¶-AGGGAATTCTGCCATGCAGAAAATCTTTGC-3¶
(forward) and 5¶-ATTGAATTCTCACTTGGCCTTCGGGTT-3¶ (reverse).
The resultant fragments were digested with EcoRI, cloned into pBlue-
Script-myc vector, and overexpressed in HeLa cells by infection of T7
vaccinia viruses as described previously (27). Construction of the human
ENO1 gene in pBlueScript-myc was done in the same manner.
Immunoblotting. To detect p48, ENO-1, ENO-2, ENO-3, or Myc-
tagged proteins, 50 Ag of cell lysates were resolved by 10% SDS-PAGE
using appropriate antibodies in Western blotting analyses, which were
described in each figure legends. The immunocomplex was visualized
by SuperSignal chemiluminescence (Pierce). Glyceraldehyde-3-phos-
phate dehydrogenase and h-actin are loading controls. The ENO2- and
ENO3-specific monoclonal antibodies were obtained from Abnova Co.
(Taipei, Taiwan, Republic of China).14 Myc-tag (9E10), glyceraldehyde-
3-phosphate dehydrogenase, and h-actin were purchased from Upstate
Biotechnology (Lake Placid, NY), Biogenesis (Poole, United Kingdom),
and Sigma Co. (St. Louis, MO), respectively.
Patients. The acquisition of paraffin tissues was approved by local
Institutional Review Boards. Formalin-fixed, paraffin-embedded tissue
samples were obtained from 80 patients with NSCLC, including
40 squamous cell carcinoma, 31 adenocarcinoma, 4 adenosquamous
cell carcinoma, and 5 large cell carcinoma. The histology of tumor types
was determined according to WHO classification, and disease stages
were scored by tumor size and node metastasis. No patients received
either adjuvant or neoadjuvant therapy. Surgery was done from January
2000 to December 2001 with complete follow-up at Taichung Veterans
General Hospital (Taichung, Taiwan, Republic of China). Clinical data
of the patients are summarized in Table 1. Progression-free survival
(PFS) was calculated from the date of surgery to the date of disease
recurrence or death. Data for patients who were alive and relapse-free
were censored as of the date of the last following-up visit. Overall
survival (OS) was counted from the date of surgery to the date of
death. Eighty patients were followed for up to 60 months after surgery.
The median follow-up duration of the patients was 29.5 months.
Among these 80 patients, 30 patients died as a result of lung cancer and
had a median OS of 10 months ranging from 2 to 42 months. Forty-five
patients experienced disease recurrence.
Immunohistochemistry. Immunohistochemistry was done using a
conventional method. The sections were rehydrated, washed with PBS,
and followed by incubation with the ENO1 antiserum (1:2,000). The
specificity of the antiserum was also examined by staining sections of
the same tissue block with preimmunized serum, antiserum against
GST tag, or ENO1 antiserum preabsorbed with 1 mg of membrane-
immobilized ENO1 antigen in 1:2,000 dilution. After the sections were
incubated with biotinylated secondary antibody, the avidin-biotin
complex method was visualized by exposing sections to 3,3¶-diamino-
benzidine solution (DAKO, Carpinteria, CA) and the slides were
counterstained with hematoxylin.
Quantification of ENO1 expression and statistical analysis. The
expression status of ENO1 was assessed semiquantitatively using Quick
score method (28) at a final magnification of 200 independently
by two pathologists in a blinded manner. Conflicting scores were
Table 1. Correlation of expression status of ENO1 and patient-related clinical variables using Quick score of
5 as a cutoff value
Variable ENO1 expression
Total, n (%) Score <5, n (%) Score z5, n (%) P (univariate) P (multivariate)
Quick score 80 (100) 17 (21) 63 (79) 1.0 0.926
Medium age (y)
<65 29 (36) 6 (21) 23 (79) 1.0 0.926
z65 51 (64) 11 (22) 40 (78)
Gender
Male 69 (86) 15 (22) 54 (78) 1.0 0.789
Female 11 (14) 2 (18) 9 (82)
Smoking status
No 25 (31) 8 (37) 17 (68) 1.0 0.665
Yes 55 (69) 15 (27) 40 (73)
Histology
SCC 40 (50) 8 (20) 32 (80) 1.0 0.785
Non-SCC 40 (50) 9 (22) 31 (78)
AdenoCA 31 (39) 6 (19) 25 (81) 0.787 0.742
Non-adenoCA 49 (61) 11 (22) 38 (78)
Stage
I + II 51 (64) 15 (29) 36 (71) 0.022* 0.018*
III 29 (36) 2 (7) 27 (93)
Recurrence
No 35 (44) 12 (34) 23 (66) 0.015* 0.012*
Yes 45 (56) 5 (11) 40 (89)
NOTE: Univariate analysis was done using Fisher’s exact test. Multivariate analysis was done using logistic regression method.
Abbreviations: SCC, squamous cell carcinoma; adenoCA, adenocarcinoma.
*P < 0.05, indicates statistically significant.
14 http://www.abnova.com.tw.
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resolved at a discussion microscope. The Quick score method is a
semiquantified approach based on intensity and heterogeneity of
immunohistochemical staining and has been shown to give the same
statistically significant correlations with clinical outcomes of breast
cancer patients when compared with conventional scoring termed
‘‘Category’’ system (28). The intensity of staining was scored as 0, 1, 2,
and 3 standing for negative, weak, moderate, and strong staining,
respectively. For the heterogeneity staining, the proportion of tumor
cells staining positively was scored as follows: 0, 0%; 1, 1% to 25%;
2, 26% to 50%; 3, 51% to 75%; 4, 76% to 100%, compared with the
total of tumor cells. Scores obtained from intensity and heterogeneity
of positivity were added to give a final Quick score ranged from 0 to 7.
The numbers of patients with respect to the intensity and distribution
of ENO1 staining are shown in Supplementary Table S1 file.
Because a large number of tumors highly expressed ENO1, the score
for the immunohistochemical staining all shows z3. None of the
score gave a fair separation between patients with different clinical
variables shown in Table 1. We tested a cutoff value for Quick score
system starting from the score 3 to 7. Because of a limited number of
80 patients in the score of <4 or z7, reasonable scores are the score
of 5 or 6. Using the score of 6 as a cutoff value, none of clinical variables
were significantly associated with ENO1 expression status. Therefore,
the score of 5 as a cutoff value was chosen for continuing following
analyses and to define higher or lower expression of ENO1 in tumors.
The associations between ENO1 expression status (score <5 or z5)
and clinical variables were calculated with univariate (Fisher’s exact test)
and multivariate (logistic regression) methods. Survival curves for
PFS and OS were plotted according to Kaplan-Meier method, and
significances of differences between groups were analyzed by a log-
rank test. A Cox multivariate analysis was used to further explore
observed differences and identify factor(s) independently contributing
to survivals of cancer patients. The factors included in this analysis were
the expression status of ENO1, age, gender, smoking status, histologic
types, tumor stages, and recurrence status shown in Table 1. P < 0.05
is considered to be statistically significant.
Results
p48 antigen recognized by CA926 autologous effusion anti-
bodies. To detect existing humoral immunity in pleural
effusions, we examined 54 lung cancer patients by Western blot
analyses of tumor cell–enriched fractions with purified auto-
logous effusion antibodies. Enrichment of effusion-associated
tumor cells was carried out by serial gradient centrifugations
with Ficoll and Percoll as described previously (23). Subse-
quently, using morphologically normal lung tissues as a control
lysate in Western blotting analyses, we have detected 4 of
54 patients with antibodies recognizing one or two proteins
overexpressed or uniquely expressed in the autologous tumor
cells. However, none of distinct proteins were detected in 21
patients with non-tumor-associated diseases in this screening
(data not shown). Patient CA926 is one of the four patients
whose effusion antibodies specifically recognize a 48-kDa (p48)
major protein in autologous tumor cells. The same antigen
also appeared in another effusion cancer cell line, L89. The
antigen identity was confirmed by a competition experiment
using CA926 effusion antibodies preabsorbed with the L89
lysate (Fig. 1A). Therefore, this cell line was used as the source
for the protein identification in this study.
Purification and identification of p48 antigen. Identification
of the p48 antigen was done by biochemical purification and
mass spectrometry analysis (Fig. 1B; Supplementary Fig. S1).
Enrichment of the p48 antigen was carried out by DEAE
chromatography purification, ammonium sulfate ‘‘salting-out’’
Fig. 1. Purification and identificationof immunogenic p48 antigen ashuman ENO1.
A, top, p48-enriched lysate (30 Ag) fromeach cells was electrophorized and
immunoblottedwith CA926 antibodies or the antibodies preabsorbedwith
immobilized L89 lysate.The immunoreactionswere carriedout in an incubation
manifold (Hoefer, SanFrancisco, CA).Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH)wasused as a protein loading control. Left, molecular weightmarkers in
kDa.B, detergent-soluble L89 lysatewas dialyzed andpreclearedby centrifugation
before purification. a, lysatewas loadedonto aDEAE column.Thebounded
proteinswere fractionatedby increasing concentrationof NaCl.Westernblotting of
unbound (UB), washout (W) lysates, and each fractionated elutants (F1-F7) was
done and probed with CA926 effusion antibodies. b, unbound p48-enriched
lysates were further fractionated with saturated ammonium sulfate, ranged from
0% to 80%, and immunodetected with CA926 antibodies. c, ammonium sulfate ^
fractionated lysates were resolved on10% SDS-PAGE in duplicate. Onewas probed
with CA926 antibodies.The other was visualized by silver staining.The putative
immunoreactive protein band in the gel was excised formass spectrometry analysis.
C, gene encoding for human a-enolase (ENO1) was cloned out from L89 cells
and expressed as a GST fusion protein. Bottom,Western blotting of1 Ag of GST
tag protein and ENO1recombinant protein with or without thrombin (TB) treatment
was hybridized with either GSTor CA926 antibodies.
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precipitation, and SDS-PAGE separation. The DEAE column
buffered with 20 mmol/L Tris-HCl (pH 7.0) optimally bound
94.6% of loaded proteins but excluded the p48 from the
column. The flow-through and wash fractions containing p48
subsequently were fractionated with increasing saturations of
ice-cold ammonium sulfate. The result indicates that the
antigen was concentrated primarily in a 60% to 80% fraction.
The enriched fraction was then electrophorized and visualized
by silver staining. The corresponding immunoreactive protein
band was excised for mass spectrometry analysis. As data
shown in Supplementary Fig. S1, six trypsinized peptides were
sequenced and the p48 antigen was identified as human
a-enolase (ENO1; 2-phospho-D-glycerate hydrolase). To con-
firm ENO1 as the target of CA926 antibodies, the gene
encoding ENO1 was cloned out from the L89 cells and
fused with GST tag sequence for protein purification. The tag
protein was then removed by thrombin enzymatic digestion.
Western blot in Fig. 1C clearly shows that CA926 antibodies
specifically recognize ENO1 and its fusion proteins but not the
GST, confirming that ENO1 is the major immunogenic target
of CA926 effusion antibodies in the tumor cells.
Isoform-specific recognition of CA926 antibodies. Because the
three mammalian cloned isoforms of enolase share f84%
protein sequence identity, we first checked for the presence of
these isoforms in CA926 and L89 cells. Using isoform-specific
primers, reverse transcription-PCR analyses showed that CA926
cells expressed both ENO1 and ENO2 but not ENO3, whereas
only ENO1 was detected in L89 cells (Fig. 2A). To investigate
the specificity of CA926 effusion antibodies, the genes
encoding ENO2 and ENO3 were cloned out from CA926 and
human heart cDNA pools, respectively, and expressed in HeLa
cells. As shown in Fig. 2B, CA926 antibodies consistently
exhibited high specificity to ENO1 but failed to recognize
ENO2 and ENO3. However, when further detecting titers of
ENO1-specific effusion antibodies in those patients, Western
blotting analysis surprisingly showed only 7.4% of the cancer
patients, including patient CA926, versus 52.3% of the non-
cancer patients to have the antibody (data not shown). ELISA
analyses using the purified recombinant ENO1 as a target
consistently showed significantly lower titers of anti-ENO1
antibodies found in the cancer patients compared with those in
patients with non-cancer-associated diseases and healthy
subjects (Supplementary Fig. S2). The concentrations of total
immunoglobulins (IgA, IgG, and IgM) were still unchanged,
suggesting that ENO1-mediated immune modulation probably
occurs in the majority of the lung cancer patients.
Overexpression of ENO1 in lung tumor cells and tissues. To
test whether ENO1 is abnormally expressed in tumor cells, two
types of human lung primary cells, normal human bronchial
epithelial and small airway epithelial cells, were used for
controls. We raised rabbit antiserum against recombinant
ENO1 protein and examined its specificity to individual
isoforms of enolase by Western blotting and immunoprecipi-
tation analyses. As shown in Fig. 2B, the antiserum clearly
shows ENO1-restricted recognition. To determine ENO1
Fig. 2. Specificities of CA926 and rabbit ENO1antibodies (Ab) to enolase
isoforms. A, total RNAwas extracted from L89 or CA926 tumor cells and reverse
transcribed into cDNA pools. Abundance of each isoform gene was determined by
reverse transcription-PCR analysis using a pair of isoform-specific primer as listed in
Materials and Methods. b-Actin gene was used as an internal control. B, top, HeLa
cells were transfected with a plasmid expressing Myc-tagged ENO1, ENO2, ENO3,
or empty vector (Myc-tag). Left,Western blot of each transfected lysates was
resolvedon a10%SDS-PAGE andprobedwith antibodies. For immunoprecipitation
(IP) experiment, each transfected HeLa lysate was hybridized with ENO1
antiserum, precipitated with protein G beads, and probed for Myc-tagged proteins.
Right, endogenous ENO1in HeLa cells was labeled.
Fig. 3. Overexpression and surface staining of ENO1in effusion tumor cells.
A, tumor or mesothelial cells were obtained from pleural effusions of 17 patients
with lung cancer or 6 patients with non-cancer-associated diseases, respectively.
Among them, tumor cells from four cancer patients, including L89 cells, and
effusion cells from two control patients are representative cases. Normal human
bronchial epithelial (NHBE) and small airway epithelial (SAEC) cells are normal
human lung primary cells.WI38 is lung embryonic fibroblast cell line. Cell lysates
(30 Ag) were resolved on10% SDS-PAGE and immunoblotted with ENO1
antiserum. After stripping, the same blot was reprobed with h-actin antibody as a
loading control. B, intact whole cells were stained with (dark line) or without
(gray line) ENO1antiserum. L89, CA926, and two lung primary control cells are
representative cases.
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expression level in effusion cells, 17 of 54 patients with lung
cancer and 6 of 21 patients with non-cancer-associated diseases
containing sufficient amount of effusion cells were examined.
CA926, L89, and 11 of 17 patients have at least 2-fold increase
in ENO1 expression when compared with its level in normal
human bronchial epithelial, small airway epithelial, and
effusion cells from the 6 control patients (Fig. 3A). Intriguingly,
these overexpressed tumor cells all stained positive for cell
surface ENO1 as well (Fig. 3B), supporting previous studies
(8, 29) that surface ENO1 may have a role in promotion of
plasmin generation or cell invasion.
To determine the expression of ENO1 in lung tumors,
immunohistochemical analyses were done on 80 samples. The
tumor parts in all samples manifested clear evidence of ENO1
immunoreactivity. More than 25% of total tumor cells were
stained positively in 76 of 80 samples. Dominant cytoplasmic
staining was observed in all tumor sections (Fig. 4A, C, and D);
additionally, distinct membranous or nuclear staining was also
detected in some tumor cells. In contrast, stromal tissues
adjacent to tumors and normal-like alveolar epithelial cells
distal to tumors showed low basal staining (Fig. 4A and C).
Notably, alveolar cells proximal to the tumor displayed
increasing immunoreactivity in either the cytoplasmic, nuclear,
or membranous regions (Fig. 4C, inset, arrows). Another two
negative controls using ENO1 antiserum preabsorbed with
immobilized purified ENO1 antigen (Fig. 4B) and antiserum
against GST protein (data not shown) were also included in this
study. Data taken from Western blot and immunohistochem-
ical analyses strongly indicate that increased ENO1 expression
is prevalent in patients with NSCLC.
Association of ENO1 expression with clinical outcomes. To
evaluate the relevance of ENO1 expression with clinical
outcomes of the patients, its expression status was quantified
by Quick score method (28). When a cutoff value of score 5
was used, expression status of ENO1 in tumor tissue was
significantly correlated with tumor stages (P = 0.018) and
disease recurrence (P = 0.012) shown in Table 1. Tumors in
patients with stage III disease (93%) or disease recurrence
(89%) had higher ENO1 overexpression (score z5) compared
with patients with stage I/II disease (71%) or no detected
recurrence (66%). No statistical differences in age, gender,
smoking status, or histologic subtypes were found between
patients with lower (<5) or higher (z5) ENO1 expression.
Survival analysis according to Kaplan-Meier method revealed
significant correlation between ENO1 expression status and
either PFS or OS in all patients (Fig. 5A and B). With log-rank
test, we first tested association between patients with stage I/II
and III disease (Supplementary Fig. S3). As expected, patients
with stage III disease had much poorer PFS and OS than
patients with stage I/II disease. Similarly, in Fig. 5A and B,
patients with tumors expressing higher levels of ENO1 (score
z5) also bore a tight correlation with poorer PFS and OS
significantly (P = 0.0099 and 0.0027, respectively). Moreover,
to avoid a bias favoring higher ENO1 expression as a poor
prognosis marker due to a large number of stage III tumors with
the score >5, patients with stage I/II disease were included for
analysis. Results in Fig. 5C and D consistently showed that its
expression level was reversely correlated with PFS and OS
significantly (P = 0.04 and 0.034, respectively). Moreover,
when even using the score of 6 as a cutoff value, log-rank
survival analyses also show that stage I/II patients with tumors
expressing ENO1 level <6 have a good prognosis for PFS
(P < 0.001) and a better trend for OS (P = 0.18), although the
score of 6 as a cutoff value for ENO1 expression was shown
no significant association with the clinical variables (Supple-
mentary Table S2). Thus, these data strongly support a
potential prognostic role of ENO1 expression for NSCLC
patients.
Cox multivariate analysis was used to test contribution of
ENO1 expression status, tumor stage and/or disease recurrence,
age, gender, smoking status, and histologic subtypes on PFS
and OS of the patients. Only ENO1 expression with score z5
proved to be associated with poor PFS (P = 0.031). In contrast,
stage I/II disease was shown to have a better trend on PFS
(P = 0.076). Additionally, both lower ENO1 expression
(score <5) as well as free of disease recurrence were emerged
as strong factors contributing on better OS outcomes (P = 0.008
and 0.003, respectively). Taken together, these data strongly
support expression status of ENO1 to be a potent prognostic
marker for survival outcomes of NSCLC patients.
Discussion
Because molecular identity of tumor-associated antigens is first
discovered in melanoma patients, this finding has led to
elucidation of tumor immunity, including cellular and humoral
immunities, at a cellular and molecular level. Interestingly, the
majority of these antigens characterized to date are unaltered self-
antigens. In the present study, we also identified a 48-kDa
protein of CA926 tumor cells as unaltered human a-enolase
(ENO1), which is recognized by autologous effusion antibodies.
As predicted by a previous bioinformative study (20), ENO1 is
overexpressed in lung cancer in our study. About 65% of patients
with effusion tumor cells and all the tumor samples we have
examined thus far consistently show up-regulation of ENO1 gene
expression in the tumors compared with that in normal primary
lung epithelial cells and tumor-adjacent normal tissue counter-
parts. Moreover, the statistical analyses correlating ENO1
expression in the patients with their clinical outcomes further
reveal that the expression status of ENO1 is highly associated
with survival and disease recurrence of NSCLC patients.
Overexpression of unaltered antigen(s) in malignant cells is
believed to be one of possible mechanisms to initial tumor
immunity (30), whereas the immunity is eventually suppressed
resulting in tumor escape. B7-H1 (31), IDO (32), RCAS1 (33),
etc. have been shown to overexpress in a variety of cancers,
including lung cancer. However, autoantibodies immunoreac-
tive to these antigens are rarely reported in cancer patients but
associated with some inflammatory or metabolic diseases
(34, 35), implicating that tumor antigen-mediated immuno-
suppression may occur in tumor malignancy. Consistent with
previous studies to detect CML28 (36) and ENO1 (14)
autoantibodies in chronic myelogenous leukemia and lung
patients, respectively, our data obtained from Western blotting
analyses also show that only a small percentage (7.4%) of the
cancer patients, including patient CA926, develop high titer of
antibodies against ENO1. The same conclusion is also observed
when a sandwich ELISA to quantify levels of the autoantibodies
was used, showing that the levels in the cancer patients are
significantly lower (P < 0.01) than those in effusion fluids
of the non-tumor-associated patients and in sera of healthy
control subjects (Supplementary Fig. S2).
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Failure to exert antitumor effect may be associated with
defects in complement-mediated cytotoxicity. Because anti-
body-induced complement attack is one of main themes for
tumor cell lysis, quantitative requirement of C3 to activate
downstream membrane attack complex is indispensable (37).
Thus, we further detected levels of C3 and C4 in patient CA926.
The values are 29.2 mg/dL for C3 and 4.7 mg/dL for C4, which
all are far below reference ranges (C3, 90-180 mg/dL; C4, 10-40
mg/dL). This preliminary data suggest that lack of sufficient
amount of C3 and C4 may account for, at least partially, tumor
escape in patient CA926. Intriguingly, a recent study showed
that treatment of mice with the recombinant bacterial enolase
could stimulate production of interleukin-10, a pro-Th2
cytokine (38). Therefore, it would be interesting to further
investigate whether overexpression of ENO1 in malignant cells
is involved in Th1 and Th2 switch because active CD4+ T help
cells have indispensable role in development and maintenance
of CTLs and antibody-secreting B cells.
Up-regulation of glycolytic enzymes is a common scenario in
a variety of cancers. In response to hypoxia, normal cells will
increase gene expression of glycolytic enzymes to adapt
environmental stress through activation of hypoxic-inducible
transcription factor (39). However, this cellular process is
reversible for normal cells but irreversible for malignant cells.
Moreover, tumor cells preferentially use anaerobic glycolysis for
inefficient energy metabolism (Warburg effect), leading to
increase difficulties for disease treatment. More recently,
oncogenic AKT and Myc have been shown to stimulate
anaerobic glycolysis directly and ENO1 is one of the Myc-
driven target genes (40). Thus, elevated level of ENO1 gene
expression seems to be an inevitable consequence during
tumorigenesis. Consistent with previous reports on cell line
studies, we further show that ENO1 is overexpressed in patients
with lung cancer and its high levels (score z5) are tightly
correlated with poor prognoses.
However, a previous study (21) obtaining a conclusion
different from ours may be attributed to different isoform-
specific antibodies used in the experiments. Because the three
known isoforms of mammalian enolases are highly conserved
in protein sequence (f84% protein identity), it would be a
difficult task to generate isoform-specific antibody for each of
them. We raised antisera against purified recombinant ENO1
protein from three rabbits. Only antiserum from one rabbit
displayed high specificity to ENO1. To confirm its recognition
specificity, we cloned out all the isoforms and showed its
specificity in three ways: (a) immunoreactivity of the antibody
specific to ENO1 but not to human ENO2 and ENO3 in
Western blotting analyses (Fig. 2B), (b) capability and
specificity of the antibody to immunoprecipitate ENO1, and
(c) abolishment of immunohistochemical staining by absorp-
tion of the antibody with the purified recombinant ENO1
(Fig. 4). Using the antibody, we exhibit relatively lower levels of
ENO1 in two human primary lung epithelial cell controls and
normal lung tissues compared with those in effusion tumor
cells and tumor tissues. These data corroborate Holland et al.
(41) initial observations that showed an increased expression
Fig. 4. Immunohistochemical staining of ENO1in lung tumor tissues.Tissue
sections from patients with lung cancer were examined immunohistochemically.
Transverse serial sections were obtained from a patient with lung adenocarcinoma
(AdenoCA) and stained with ENO1antiserum (A) or ENO1antiserum preabsorbed
with immobilized GST-fused ENO1antigen (B) to show specificity of ENO1
antiserum. Normal-like alveolar epithelial cells proximal to the tumor part (arrows)
displayed increasing staining of ENO1in either cytoplasm, nuclear, or membrane
(inset, arrows), whereas the distal alveolar walls (C) showed low basal expression.
D, inset, adenocarcinoma cells in another patient also showed high level of
cytoplasm staining of ENO1. Magnifications,100 (A-D) and 200 (C and D,
insets). Bar, 100 Am.
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of ENO1 in exponentially growing cells, whereas expression in
resting phase cells was at very low levels. In contrast to our
antiserum, because the specificity of 9G12 antibody to ENO1
used in the previous report (21) has not been seen in any
published data, we suspect that 9G12 could be typing error for
9C12. The 9C12 antibody, originally developed from Redlitz’s
laboratory (8), recognizes both 54-kDa and 48-kDa proteins in
U937 lysates and ENO1 purified from human brain, respectively,
indicating that this antibody may recognize an unidentified
a-enolase-related molecule besides ENO1. Furthermore, its cross-
reactivity to ENO2 is not clear because ENO1 epitope sequence
of 9C12 antibody (42) shares 81.3% protein identity with
human ENO2 protein. ENO2 (g-enolase) not only abundantly
exists in neural and bronchopulmonary neuroendocrine cells
(43) but also expresses in normal nonneuron tissues (44),
including bronchial and type II alveolar epithelial cells.
To further explore if existence of distinct amount of ENO2
in lung carcinoma might account for different outcomes
between two laboratories, we adopted Western blotting
analysis of two pairs of normal and tumor counterpart lysates
for detection of ENO-1, ENO-2, and ENO-3 expressions.
Antibody specificity to each isoform of enolases was shown in
Fig. 2B. Using those antibodies, a preliminary study clearly
showed one of the two tumor lysates displaying significant
down-regulation of ENO2 compared with that in its normal
counterpart (Supplementary Fig. S4). In contrast, ENO1 is still
consistently up-regulated in both tumor parts. Therefore,
isoform specificity of antibody used for detection of ENO1
becomes a key issue to correctly interpret resultant clinical
outcomes of cancer patients.
Changes in energy metabolism are fundamental properties of
cancer cells by which the cells survive in a state of hypoxic stress
followed by promotion of angiogenesis and enhancement of
local invasion or distal metastasis. In this study, up-regulation of
glycolytic enzymes, such as ENO1, in NSCLC patients is highly
associated with poorer clinical prognoses for tumor recurrence
and survival. Coincidently, surface ENO1 also detected in the
effusion tumor cells may implicate its potential role in cell
invasion. Using a low-invasive cell line and its invasive coun-
terpart, we preliminarily support this implication.15 Conclu-
sively, we developed an antibody and showed its specificity
exclusive to ENO1 in this study. Using this antibody, we show
that increasing expression of ENO1 is a prevailing phenomenon
in patients with NSCLC and its expression status is tightly
correlated with disease recurrence and survival. Hence, ENO1
can be a good prognostic indicator to monitor disease
progression for NSCLC patients, but also, its surface-localized
antigen may serve as a target of immunotherapy for cancers in
future.
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